Flossbach Von Storch AG Buys 1,443,558 Shares of Becton Dickinson and Co (NYSE:BDX)

Flossbach Von Storch AG raised its stake in Becton Dickinson and Co (NYSE:BDX) by 334.5% during the first quarter, Holdings Channel.com reports. The institutional investor owned 1,875,063 shares of the medical instruments supplier’s stock after purchasing an additional 1,443,558 shares during the quarter. Becton Dickinson and accounts for about 2.9% of Flossbach Von Storch AG’s portfolio, making the stock its 12th largest position. Flossbach Von Storch AG’s holdings in Becton Dickinson and were worth $430,833,000 at the end of the most recent quarter.

Other large investors also recently modified their holdings of the company. Ascent Wealth Partners LLC increased its holdings in shares of Becton Dickinson and by 1.3% in the 1st quarter. Ascent Wealth Partners LLC now owns 30,782 shares of the medical instruments supplier’s stock worth $7,073,000 after buying an additional 389 shares during the last quarter. Fjarde AP Fonden Fourth Swedish National Pension Fund increased its holdings in shares of Becton Dickinson and by 8.9% in the 4th quarter. Fjarde AP Fonden Fourth Swedish National Pension Fund now owns 80,455 shares of the medical instruments supplier’s stock worth $21,881,000 after buying an additional 6,600 shares during the last quarter. KBC Group NV increased its holdings in shares of Becton Dickinson and by 29.1% in the 4th quarter. KBC Group NV now owns 109,904 shares of the medical instruments supplier’s stock worth $29,891,000 after buying an additional 24,750 shares during the last quarter. Caisse DE Depot ET Placement DU Quebec increased its holdings in shares of Becton Dickinson and by 47.0% in the 4th quarter. Caisse DE Depot ET Placement DU Quebec now owns 35,344 shares of the medical instruments supplier’s stock worth $9,613,000 after buying an additional 11,300 shares during the last quarter. Finally, Kidder Stephen W increased its holdings in shares of Becton Dickinson and by 12.0% in the 1st quarter. Kidder Stephen W now owns 17,270 shares of the medical instruments supplier’s stock worth $3,968,000 after buying an additional 1,856 shares during the last quarter. 86.79% of the stock is currently owned by hedge funds and other institutional investors.

Several equities analysts recently commented on the stock. TheStreet lowered shares of Becton Dickinson and from a “b” rating to a “c+” rating in a report on Monday, March 9th. UBS Group increased their target price on shares of Becton Dickinson and from $260.00 to $265.00 and gave the company a “neutral” rating in a report on Friday, May 8th. Citigroup increased their target price on shares of Becton Dickinson and from $234.00 to $260.00 and gave the company a “neutral” rating in a report on Friday, May 8th. Cfra reduced their target price on shares of Becton Dickinson and from $285.00 to $278.00 and set a “hold” rating on the stock in a report on Friday, May 8th. Finally, Wells Fargo & Co reaffirmed a “buy” rating on shares of Becton Dickinson and in a report on Friday, May 8th. Nine investment analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. Becton Dickinson and presently has a consensus rating of “Hold” and a consensus price target of $275.79.

Shares of NYSE:BDX traded up $0.31 on Friday, hitting $239.25. The company had a trading volume of 11,783,270 shares, compared to its average volume of 1,932,654. The firm’s 50-day simple moving average is $253.35 and its two-hundred day simple moving average is $255.35. Becton Dickinson and Co has a 1 year low of $197.75 and a 1 year high of $286.72. The company has a quick ratio of 0.66, a current ratio of 0.98 and a debt-to-equity ratio of 0.80. The firm has a market capitalization of $64.79 billion, a price-to-earnings ratio of 72.06, a P/E/G ratio of 2.57 and a beta of 0.95.

Becton Dickinson and (NYSE:BDX) last posted its earnings results on Thursday, May 7th. The medical instruments supplier reported $2.55 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $2.32 by $0.23. Becton Dickinson and had a net margin of 6.10% and a return on equity of 15.75%. The firm had revenue of $4.25 billion during the quarter, compared to analysts’ expectations of $4.10 billion. During the same period last year, the company posted $2.59 EPS. The company’s quarterly revenue was up 1.4% compared to the same quarter last year. Equities research analysts anticipate that Becton Dickinson and Co will post 10.5 EPS for the current year.

The business also recently announced a quarterly dividend, which will be paid on Tuesday, June 30th. Stockholders of record on Tuesday, June 9th will be given a $0.79 dividend. The ex-dividend date is Monday, June 8th. This represents a $3.16 annualized dividend and a dividend yield of 1.32%. Becton Dickinson and’s dividend payout ratio is 27.05%.

About Becton Dickinson and

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral IV and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, IV fluids, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps and dedicated disposables, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems.

Read More: Death Cross

Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton Dickinson and Co (NYSE:BDX).

Institutional Ownership by Quarter for Becton Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.